公开(公告)号：US10189841B2

公开(公告)日：2019-01-29

申请号：US15355887

申请日：2016-11-18

Applicant: Forma Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Stephanos Ioannidis ,  Bruce Follows ,  Gary Gustafson ,  Minghua Wang ,  Justin A. Caravella ,  Zhongguo Wang ,  Edward L. Fritzen ,  Jian Lin

IPC: A61K31/522 ,  C07D473/00

Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.

公开(公告)号：US20180327382A1

公开(公告)日：2018-11-15

申请号：US15964812

申请日：2018-04-27

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  A61K31/4704

CPC classification number: C07D401/12 ,  A61K31/4704 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US20180141910A1

公开(公告)日：2018-05-24

申请号：US15568051

申请日：2015-09-18

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D215/227 ,  C07D487/04 ,  C07D498/04 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D405/12 ,  C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D215/227 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D519/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US20180118732A1

公开(公告)日：2018-05-03

申请号：US15568072

申请日：2015-09-18

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D417/12 ,  C07D471/04 ,  C07D417/14 ,  A61P35/00

CPC classification number: C07D417/12 ,  A61P35/00 ,  C07D417/14 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: (I) where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.

公开(公告)号：US09834539B2

公开(公告)日：2017-12-05

申请号：US14858167

申请日：2015-09-18

Applicant: Forma Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04

CPC classification number: C07D401/12 ,  A61K31/47 ,  C07D401/14 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US09771349B2

公开(公告)日：2017-09-26

申请号：US14858170

申请日：2015-09-18

Applicant: Forma Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  A61K31/4704 ,  C07D413/14 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14

CPC classification number: C07D401/12 ,  A61K31/4704 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US20170145012A1

公开(公告)日：2017-05-25

申请号：US15355887

申请日：2016-11-18

Applicant: Forma Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Stephanos Ioannidis ,  Bruce Follows ,  Gary Gustafson ,  Minghua Wang ,  Justin A. Caravella ,  Zhongguo Wang ,  Edward L. Fritzen ,  Jian Lin

IPC: C07D473/00

CPC classification number: C07D473/00 ,  A61K31/522

Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.

公开(公告)号：US20160311774A1

公开(公告)日：2016-10-27

申请号：US14858159

申请日：2015-09-18

Applicant: Forma Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D215/227 ,  C07D413/12 ,  C07D498/04 ,  C07D401/12 ,  C07D487/04 ,  C07D471/04 ,  C07D417/12 ,  C07D405/12

CPC classification number: C07D215/227 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D519/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

Abstract translation: 其中A，B，U，V，Z，W1，W2，W3和R1-R6。

公开(公告)号：US12043623B2

公开(公告)日：2024-07-23

申请号：US17490482

申请日：2021-09-30

Applicant: Forma Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Stephanos Ioannidis ,  Bruce Follows ,  Gary Gustafson ,  Minghua Wang ,  Justin Andrew Caravella ,  Zhongguo Wang ,  Edward L. Fritzen ,  Jian Lin

IPC: C07D473/00 ,  A61K31/522

CPC classification number: C07D473/00 ,  A61K31/522

Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula:




where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.

公开(公告)号：US20220315565A1

公开(公告)日：2022-10-06

申请号：US17668621

申请日：2022-02-10

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.